vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI). Click either name above to swap in a different company.
COGENT COMMUNICATIONS HOLDINGS, INC. is the larger business by last-quarter revenue ($240.5M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -4.7%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -4.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Cogent Communications Holdings, Inc. is a multinational internet service provider based in the United States. Cogent's primary services consist of Internet access and data transport, offered on a fiber optic, IP data-only network, along with colocation in data centers.
AXSM vs CCOI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $240.5M |
| Net Profit | — | $-30.8M |
| Gross Margin | — | 46.6% |
| Operating Margin | -33.1% | -4.7% |
| Net Margin | — | -12.8% |
| Revenue YoY | 57.4% | -4.7% |
| Net Profit YoY | — | 28.9% |
| EPS (diluted) | — | $-0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $240.5M | ||
| Q3 25 | $171.0M | $241.9M | ||
| Q2 25 | $150.0M | $246.2M | ||
| Q1 25 | $121.5M | $247.0M | ||
| Q4 24 | $118.8M | $252.3M | ||
| Q3 24 | $104.8M | $257.2M | ||
| Q2 24 | $87.2M | $260.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-30.8M | ||
| Q3 25 | $-47.2M | $-41.5M | ||
| Q2 25 | $-48.0M | $-57.8M | ||
| Q1 25 | $-59.4M | $-52.0M | ||
| Q4 24 | $-74.9M | $-43.3M | ||
| Q3 24 | $-64.6M | $-63.1M | ||
| Q2 24 | $-79.3M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 46.6% | ||
| Q3 25 | — | 45.6% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 40.0% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -4.7% | ||
| Q3 25 | -27.0% | -7.5% | ||
| Q2 25 | -24.5% | -12.8% | ||
| Q1 25 | -46.9% | -16.3% | ||
| Q4 24 | -61.1% | -13.2% | ||
| Q3 24 | -59.8% | -22.5% | ||
| Q2 24 | -89.5% | -18.1% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -12.8% | ||
| Q3 25 | -27.6% | -17.2% | ||
| Q2 25 | -32.0% | -23.5% | ||
| Q1 25 | -48.9% | -21.1% | ||
| Q4 24 | -63.1% | -17.2% | ||
| Q3 24 | -61.7% | -24.5% | ||
| Q2 24 | -91.0% | -12.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.63 | ||
| Q3 25 | $-0.94 | $-0.87 | ||
| Q2 25 | $-0.97 | $-1.21 | ||
| Q1 25 | $-1.22 | $-1.09 | ||
| Q4 24 | $-1.54 | $-0.89 | ||
| Q3 24 | $-1.34 | $-1.33 | ||
| Q2 24 | $-1.67 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $148.5M |
| Total DebtLower is stronger | $70.0M | $1.7B |
| Stockholders' EquityBook value | — | $-63.8M |
| Total Assets | $713.6M | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $148.5M | ||
| Q3 25 | $325.3M | $147.1M | ||
| Q2 25 | $303.0M | $213.7M | ||
| Q1 25 | $300.9M | $153.8M | ||
| Q4 24 | $315.4M | $198.5M | ||
| Q3 24 | $327.3M | $279.2M | ||
| Q2 24 | $315.7M | $384.4M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $-63.8M | ||
| Q3 25 | $73.7M | $-39.2M | ||
| Q2 25 | $73.1M | $46.7M | ||
| Q1 25 | $53.2M | $142.8M | ||
| Q4 24 | $57.0M | $222.8M | ||
| Q3 24 | $92.9M | $323.6M | ||
| Q2 24 | $102.9M | $415.5M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $3.1B | ||
| Q3 25 | $669.3M | $3.1B | ||
| Q2 25 | $639.8M | $3.3B | ||
| Q1 25 | $596.7M | $3.1B | ||
| Q4 24 | $568.5M | $3.2B | ||
| Q3 24 | $561.5M | $3.2B | ||
| Q2 24 | $548.2M | $3.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.53× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-6.0M |
| Free Cash FlowOCF − Capex | — | $-43.0M |
| FCF MarginFCF / Revenue | — | -17.9% |
| Capex IntensityCapex / Revenue | — | 15.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-198.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-6.0M | ||
| Q3 25 | $1.0M | $3.1M | ||
| Q2 25 | $-32.4M | $-44.0M | ||
| Q1 25 | $-43.4M | $36.4M | ||
| Q4 24 | $-26.2M | $14.5M | ||
| Q3 24 | $-18.6M | $-20.2M | ||
| Q2 24 | $-30.1M | $-22.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-43.0M | ||
| Q3 25 | $988.0K | $-33.1M | ||
| Q2 25 | $-32.4M | $-100.2M | ||
| Q1 25 | $-43.7M | $-21.7M | ||
| Q4 24 | $-26.2M | $-31.6M | ||
| Q3 24 | $-18.7M | $-79.5M | ||
| Q2 24 | $-30.2M | $-70.9M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -17.9% | ||
| Q3 25 | 0.6% | -13.7% | ||
| Q2 25 | -21.6% | -40.7% | ||
| Q1 25 | -36.0% | -8.8% | ||
| Q4 24 | -22.1% | -12.5% | ||
| Q3 24 | -17.9% | -30.9% | ||
| Q2 24 | -34.6% | -27.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 15.4% | ||
| Q3 25 | 0.0% | 15.0% | ||
| Q2 25 | 0.0% | 22.8% | ||
| Q1 25 | 0.3% | 23.5% | ||
| Q4 24 | 0.0% | 18.3% | ||
| Q3 24 | 0.1% | 23.0% | ||
| Q2 24 | 0.1% | 18.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CCOI
Segment breakdown not available.
